Technologies for Human Cellular Immunology

研究资源技术开发部分(TDC)将开发新的 A-C类病毒T细胞表位的快速鉴定技术 并用于分析人类外周血样本中的抗原特异性T细胞。这个 拟议研究的具体目标是：同时开发技术 基于MHC-多肽复合体固相阵列的多种T细胞表位研究 建立T细胞表位鉴定和抗原特异性T细胞检测的方法 在抗原提呈细胞阵列上；开发基于蛋白质组学的新方法 抗原特异性T细胞的功能鉴定；发展基因芯片和蛋白质组学 A-C类MHC结合肽的简便鉴定方法 病毒；评价这些方法在鉴定T细胞抗原方面的有效性 和针对A-C类病毒的T细胞，并将这些方法进行比较，以呈现 并验证其在继续研究中的使用。由该组织开发的方法 组件将在研究项目确定的明确定义的测试系统中进行评估， 研究项目将使用经过验证的方法来分析人类 对痘苗病毒、汉坦病毒和黄病毒感染的细胞免疫反应 接种疫苗。我们预计该组件开发的方法将广泛应用于 在研究人类对生物防御相关病原体的免疫反应方面很有用，我们 包括传播和商业化经过验证的技术的计划。

The research resource technical development component (TDC) will develop novel technologies for the rapid identification of T cell epitopes derived from category A-C viruses and for the analysis of antigen-specific T cells in human peripheral blood samples. The specific aims of the proposed research are: to develop technology for simultaneous investigation of many T-cell epitopes based on solid-phase arrays of MHC-peptide complexes; to develop assays for T cell epitope identification and antigen-specific T cell detection based on arrays of antigen-presenting cells; to develop novel proteomics-based approaches to functional characterization of antigen-specific T cells; to develop microarray and proteomics approaches to facile identification of MHC-binding peptides derived from category A-C viruses; to evaluate the utility of these methods towards the identification of T-cell antigens and T cells specific for category A-C viruses, and to compare these methods to present technologies and validate their use for continuing studies. The methods developed by this component will be evaluated in well-defined test systems identified by the Research Projects, and validated methods will be used by the Research Projects in the analysis of the human cellular immune response to vaccinia virus, hantavirus, and flavivirus infection and vaccination. We anticipate that the methods developed by this component will be broadly useful in the study of the human immune response to biodefense-related pathogens, and we have included plans for the dissemination and commercialization of validated technologies.